Some recently published studies [1] [2] [3] have raised intriguing questions which may be clinically relevant for future clinical trials of umbilical cord blood (UCB) transplantation in adults. Using a nonobese diabetic/severe combined immunodeficiency (NOD/SCID) xenotransplant model for studying the engraftment of human rapid short-term SCID repopulating cells (R-SRC), McKenzie et al.
Some recently published studies [1] [2] [3] have raised intriguing questions which may be clinically relevant for future clinical trials of umbilical cord blood (UCB) transplantation in adults. Using a nonobese diabetic/severe combined immunodeficiency (NOD/SCID) xenotransplant model for studying the engraftment of human rapid short-term SCID repopulating cells (R-SRC), McKenzie et al.
1 demonstrated higher engraftment 2 and 6 weeks after transplanting Lin 2 Based on their findings in mice and monkey models, Ikehara et al.
3 considered intra-bone marrow (BM) transplantation a potentially important strategy.
The concept of using the IO route of infusion in emergencies is re-emerging 4 and its safety is well established. 5 In addition to IO needles and BM biopsy needles, semiautomated devices are being evaluated for this purpose. The IO route of BM transplantation, using posterior iliac crests, has already been tested successfully in a prospective randomized fashion both in children 6 and adults. 7 Although engraftment was not faster, a significant reduction in the number of days on total parenteral nutrition and a tendency toward a reduction in the number of days on antibiotics was noted in the IO compared with the IV group. 7 Interestingly bacteremia did not occur in the IO group. 7 Major obstacles in the success of UCB transplantation in adult patients include relatively smaller dose of stem cells in the graft and delayed engraftment leading to high infectious morbidity and mortality. 8 In spite of being a rich source for CD34 þ CD38 À stem cells and R-SRC, 9 some of the repopulating cells in UCB may have significantly reduced homing levels when injected IV. 1, 10 McKenzie et al. 1 showed that anti-CD122 antibody was useful in overcoming CD122 þ cell-related resistance in this xenotransplantation model, and also pointed out that faster and better engraftment in IO transplantation as compared with usual IV transplantation might be related to host resistance factors other than CD122 þ cells, preventing the homing of UCB R-SRC to appropriate hematopoetic niches within the BM. 1 Now, with the availability of a variety of growth factors, and the strategies of multiunit UCB transplantation and ex vivo expansion of UCB units being explored in studies, 8 the time may be right for testing the approach of IO transplantation of UCB as a way of overcoming the problem of delayed engraftment. We propose that this strategy be tested prospectively to compare IO route, IV route and combined IV and IO route using single or multiple UCB units. 
